The biopharma landscape has changed. In just a few years, nucleic acid therapeutics—once considered experimental—have become one of the most exciting frontiers in medicine. From mRNA vaccines to CRISPR-based therapies and antisense oligonucleotides, these molecules are reshaping how we think about treating disease. At Xoligo Biologics, we launched with a clear vision: to build a […]